R&D Pipeline
Building tomorrow's API portfolio.
Anuh's DSIR-recognised R&D centre is actively developing a pipeline of new-generation APIs across diabetes, malaria, CNS, anticoagulant and other high-value therapeutic areas — expanding our range for regulated markets.
Anti-Diabetic
Anti-Diabetic
Linagliptin
Under Development
Anti-Diabetic
Empagliflozin
Under Development
Anti-Malarial
Anti-Malarial
Pyronaridine Tetraphosphate
Under Development
Anti-Malarial
Piperaquine Phosphate
Under Development
Anti-Ulcerative
Anti-Ulcerative
Vonoprazan Fumarate
Under Development
Anti-TB
Anti-TB
Pretomanid
Under Development
Anti-Inflammatory
Anti-Inflammatory
Brensocatib
Under Development
Anticholinergic
Anticholinergic
Vibegron
Under Development
Anti-Anemic
Anti-Anemic
Vadadustat
Under Development
Anticoagulant
Anticoagulant
Edoxaban Tosylate
Under Development
Antagonist
Antagonist
Fezolinetant
Under Development
Anticonvulsant
Anticonvulsant
Cenobamate
Under Development
Anticonvulsant
Primidone
Under Development
Anticonvulsant
Phenytoin
Under Development
Antidepressant
Antidepressant
Gepirone Hydrochloride
Under Development
Antidepressant
Brexpiprazole
Under Development
Antidepressant
Vortioxetine
Under Development
Antidepressant
Mirtazapine
Under Development
Mucolytic / Expectorant
Mucolytic / Expectorant
Erdosteine
Under Development